Browsing by Author "Yasar A."

Now showing 1 - 10 of 10
  • No Thumbnail Available
    Item
    Verrucous hemangioma
    (2009) Yasar A.; Ermertcan A.; Bilac C.; Bilac D.; Temiz P.; Ozturkcan S.
    [No abstract available]
  • No Thumbnail Available
    Item
    Serum homocysteine, vitamin B12, folic acid levels and methylenetetrahydrofolate reductase (MTHFR) gene polymorphism in vitiligo
    (Hindawi Limited, 2012) Yasar A.; Gunduz K.; Onur E.; Calkan M.
    The aim of this study was to determine serum vitamin B12, folic acid and homocysteine (Hcy) levels as well as MTHFR (C677, A1298C) gene polymorphisms in patients with vitiligo, and to compare the results with healthy controls. Forty patients with vitiligo and 40 age and sex matched healthy subjects were studied. Serum vitamin B12 and folate levels were determined by enzyme-linked immunosorbent assay. Plasma Hcy levels and MTHFR polymorphisms were determined by chemiluminescence and real time PCR methods, respectively. Mean serum vitamin B12 and Hcy levels were not significantly different while folic acid levels were significantly lower in the control group. There was no significant relationship between disease activity and vitamin B12, folic acid and homocystein levels. No significant difference in C677T gene polymorphism was detected. Heterozygote A1298C gene polymorphism in the patient group was statistically higher than the control group. There was no significant relationship between MTHFR gene polymorphisms and vitamin B12, folic acid and homocysteine levels. In conclusion, vitamin B12, folate and Hcy levels are not altered in vitiligo and MTHFR gene mutations (C677T and A1298C) do not seem to create susceptibility for vitiligo. © 2012 - IOS Press and the authors. All rights reserved.
  • No Thumbnail Available
    Item
    Food-induced anaphylaxis in early childhood and factors associated with its severity
    (OceanSide Publications Inc., 2021) Aydogan M.; Topal E.; Yakici N.; Cansu H.; Demirkale Z.H.; Arga M.; Uysal P.; Aydemir S.; Simsek I.E.; Tamay Z.; Cekic S.; Cavkaytar O.; Kaplan F.; Kiykim A.; Cogurlu M.T.; Süleyman A.; Yücel E.; Akkelle E.; Hancioglu G.; Yasar A.; Tuncel T.; Nacaroglu H.T.; Aydogmus C.; Güler N.; Cokugras H.; Sapan N.; Yüksel H.; Sancak R.; Erdogan M.S.; Ozdemir O.; Ozdemir C.; Orhan F.
    Background: Several factors that increase the risk of severe food-induced anaphylaxis have been identified. Objective: We aimed to determine the demographic, etiologic, and clinical features of food-induced anaphylaxis in early childhood and also any other factors associated with severe anaphylaxis. Methods:We carried out a medical chart review of anaphylaxis cases from 16 pediatric allergy and immunology centers in Turkey. Results: The data of 227 patients with 266 food-induced anaphylaxis episodes were included in the study. The median (interquartile range) age of the first anaphylaxis episode was 9 months (6-18 months); 160 of these patients were boys (70.5%). The anaphylaxis episodes were mild in 75 cases (28.2%), moderate in 154 cases (57.9%), and severe in 37 cases (13.9%). The most frequent food allergens involved were cow's milk (47.4%), nuts (16.7%), and hen's egg (15.8%). Epinephrine was administered in only 98 (36.8%) of these anaphylaxis episodes. A logistic regression analysis revealed two statistically significant factors that were independently associated with severe anaphylaxis: the presence of angioedema and hoarseness during the anaphylactic episode. Urticaria was observed less frequently in patients who developed hypotension. In addition, confusion and syncope were associated with 25.9- and 44.6-fold increases, respectively, in the risk of concomitant hypotension. Conclusion: Cow's milk, nuts, and hen's egg caused the majority of mild and moderate-to-severe anaphylaxis episodes. The presence of angioedema and hoarseness in any patient who presents with a history of food-induced anaphylaxis should alert clinicians that the reaction may be severe. In addition, the presence of confusion, syncope, or stridor probably indicates concomitant hypotension. Copyright © 2021, OceanSide Publications, Inc., U.S.A.
  • No Thumbnail Available
    Item
    Effect of subcutaneous immunotherapy on the natural course of allergic diseases in pediatric patients: A real-life cohort
    (Galenos, 2021) Yasar A.; Yilmaz O.; Simsek Y.; Alpdogan S.; Kunay B.; Yuksel H.
    Aim: Specific allergen immunotherapy (SIT) is the only disease-modifying therapy for allergic diseases. We aimed to examine the effect of subcutaneous specific allergen immunotherapy (SCIT) applications on the prognosis of asthma and allergic rhinitis in pediatric cases in real-life settings. Methods: The study was designed as a retrospective cohort study. Patients with asthma and/or allergic rhinitis aged between 5 and 18 years old were enrolled between 2010 and 2015. The groups who received SCIT and who did not receive were compared in terms of disease severity parameters in follow-up recorded in their files. Results: A total of 298 cases, among which 140 received subcutaneous specific allergen immunotherapy. The frequency of asthma, allergic rhinitis, and co-morbidity was similar between the two groups. In the first year of the follow-up, asthma symptoms severity was not significant between the two groups; however, both asthma and allergic rhinitis symptoms were significantly lower in the SCIT patients at the end of the third year of follow-up. While the follow-up rate for three years or more was 62% in the group that received subcutaneous specific allergen immunotherapy, it was 38% in the group that did not receive. Conclusion: These results showed that SIT is an effective treatment modality in real-life settings with low side effects in pediatric patients with uncontrolled asthma and allergic rhinitis despite medical treatment. © 2021 by The Medical Bulletin of İstanbul Haseki Training and Research Hospital The Medical Bulletin of Haseki published by Galenos Yayınevi.
  • No Thumbnail Available
    Item
    Maternal psychiatric status and infant wheezing: The role of maternal hormones and cord blood cytokines
    (John Wiley and Sons Inc, 2021) Yilmaz O.; Yasar A.; Caliskan Polat A.; Ay P.; Alkin T.; Taneli F.; Odabasi Cingoz F.; Hasdemir P.S.; Simsek Y.; Yuksel H.
    Rationale: Maternal psychosocial stress might be associated with development of allergic diseases in the offspring. Objectives: To evaluate the association of maternal depression and anxiety with ever wheezing and recurrent wheezing among infants and to assess the role of maternal hypothalamo-pituatary-adrenal axis changes and fetal immune response in this association. Methods: This study encompasses two designs; cohort design was developed to evaluate the association of prenatal depression with development of wheezing in infants while nested case–control design was used to assess the role of maternal cortisol and tetranectin and cord blood interleukin 13 and interferon γ. Results: We enrolled 697 pregnant women. Elementary school graduate mother (odds ratio [OR] = 1.5, p =.06), maternal smoking during pregnancy (OR = 3.4, p =.001), familial history of asthma (OR = 2.7, p <.001) increased the risk of ever wheezing. Elementary school graduate mother (OR = 2.6, p =.002), maternal smoking during pregnancy (OR = 4.8, p <.001) and familial history of asthma (OR = 1.7, p =.01) increased the risk of recurrent wheezing. Maternal previous psychiatric disease, or Edinburgh Postnatal Depression Scale or Spielberger State-Trait Anxiety Inventory scores were not associated with wheezing. Maternal tetranectin levels were significantly higher among never wheezers compared to the ever wheezers (264.3 ± 274.8 vs. 201.6 ± 299.7, p =.04). Conclusions: In conclusion, the major risk factors for ever wheezing and recurrent wheezing were maternal smoking, level of education and family history of asthma. However, maternal depression and anxiety were not determined as risk factors for wheezing. Maternal tetranectin carries potential as a biomarker for wheezing in the infant. © 2021 Wiley Periodicals LLC
  • No Thumbnail Available
    Item
    Quality of life, anxiety and depression in patients with androgenetic alopecia
    (Medcom Limited, 2021) Bilaç C.; Öztürkcan S.; Sahin M.T.; Kutlubay Z.; Serdaroglu S.; Yasar A.; Dinç G.
    Background: Androgenetic alopecia (AGA) is a common form of hair loss, which can result in body image disorder and negative social feelings. Aim: The aim of this study was to evaluate the quality of life (QoL) and the risk of anxiety and depression in AGA patients. Method: Sociodemographic data of the patients and clinical severity of the disease were recorded. The QoL score of patient and controls was evaluated with DLQI and SF-36 instruments, their anxiety and depression risks were evaluated with HAD (HAD-A and HAD-D) instruments. Results: Sixty-eight patients with AGA were included in our study. Young male AGA patients' quality of life levels were found to be low according to role limitations due to emotional problems, emotional well-being and emotional scores of SF-36 scale and younger female AGA patients quality of life levels were also found to be low according to role limitations due to emotional problems, and emotional scores of SF-36 scale. The DLQI scores of patients of both sex were found to be sig nificantly higher compared to control group. According to anxiety and depression risk assessment with HAD scale, it was found that 28.6% and 73.5% of patients were prone to suffer from anxiety and depression respectively. Conclusion: Apart from managing alopecia, practitioners should be aware of the possible psychosocial distress of AGA patients and manage accordingly. © 2021 Medcom Limited. All rights reserved.
  • No Thumbnail Available
    Item
    Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    (Newlands Press Ltd, 2023) Kahraman S.; Erul E.; Seyyar M.; Gumusay O.; Bayram E.; Demirel B.C.; Acar O.; Aksoy S.; Baytemur N.K.; Sahin E.; Cabuk D.; Basaran G.; Paydas S.; Yaren A.; Guven D.C.; Erdogan A.P.; Demirci U.; Yasar A.; Bayoglu İ.V.; Hizal M.; Gulbagci B.; Paksoy N.; Davarci S.E.; Yilmaz F.; Dogan O.; Orhan S.O.; Kayikcioglu E.; Aytac A.; Keskinkilic M.; Mocan E.E.; Unal O.U.; Aydin E.; Yucel H.; Isik D.; Eren O.; Uluc B.O.; Ozcelik M.; Hacibekiroglu I.; Aydiner A.; Demir H.; Oksuzoglu B.; Cilbir E.; Cubukcu E.; Cetin B.; Oktay E.; Erol C.; Okutur S.K.; Yildirim N.; Alkan A.; Selcukbiricik F.; Aksoy A.; Karakas Y.; Ozkanli G.; Duman B.B.; Aydin D.; Dulgar O.; Er M.M.; Teker F.; Yavuzsen T.; Aykan M.B.; Inal A.; Iriagac Y.; Kalkan N.O.; Keser M.; Sakalar T.; Menekse S.; Kut E.; Bilgin B.; Karaoglanoglu M.; Sunar V.; Ozdemir O.; Turhal N.S.; Karadurmus N.; Yalcin B.; Nahit Sendur M.A.
    Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference. © 2023 Future Medicine Ltd.
  • No Thumbnail Available
    Item
    Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
    (BioMed Central Ltd, 2024) Kahraman S.; Hizal M.; Demirel B.C.; Guven D.C.; Gumusay O.; Uluc B.O.; Bayram E.; Gulbagci B.; Yasar A.; Davarci S.E.; Mocan E.E.; Acar O.; Isik D.; Aydin E.; Karakas Y.; Ozcelik M.; Keser M.; Okutur S.K.; Eren O.; Menekse S.; Aydin D.; Yilmaz F.; Dogan O.; Ozkanli G.; Yucel H.; Sunar V.; Aykan M.B.; Ozdemir O.; Duman B.B.; Keskinkilic M.; Sakalar T.; Inal A.; Karaoglanoglu M.; Aksoy A.; Er M.M.; Turhal N.S.; Kalkan N.O.; Sendur M.A.N.
    Highly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast cancer (MBC) patients. It has been reported that combination therapy is more effective than ET alone and is safe in elderly patients as well as young patients. Nevertheless, elderly and very old patients with HR+/HER2-MBC treated with CDK4/6 inhibitor (CDK4/6i) combinations are relatively underrepresented in randomized controlled trials. To contribute to the literature, we investigated the real-world efficacy, factors associated with survival and the rates of adverse events (AEs) of the treatment with palbociclib or ribociclib plus ET in the HR+/HER2- MBC patient cohort over the age of 65 for age subgroups. In this retrospective study, 348 patients were divided into subgroups: 65–69 years old, 70–79 years old and 80 years and older. Median PFS (mPFS) for whole group was 18.3 (95% CI,14.3–22.3) months. There was no significant difference in mPFS between age groups (p = 0.75). The estimated median OS (mOS) was 39.5 (95% CI, 24.9–54.1) months and there was no significant difference between age groups (p = 0.15). There was a meaningfull numerical difference that did not reach statistical significance in patients who received CDK4/6i treatment as the first line for MBC. Grade 3–4 AEs were reported in 42.7% for the entire group, and neutropenia was the most common (37.3%). It can be concluded that combination therapy with palbociclib or ribociclib with an ET partner has similar efficacy and is safe among subgroups of older patients diagnosed with HR+/HER2-MBC. © The Author(s) 2024.
  • No Thumbnail Available
    Item
    Inflammatory markers in exhaled breath condensate in nonasthmatic children with food allergy
    (Institute of Physics, 2024) Yilmaz O.; Tunca S.; Yasar A.; Ocalan M.; Taneli F.; Yuksel H.
    Allergy is a systemic inflammation; therefore, although the allergic symptom may be seen in a specific organ system, the effects of this inflammation may be seen in other organs. interleukin (IL) IL4, IL5 and IL13 are the major Th2 cytokines and e-cadherin is an epithelial barrier protein. The objective of this research was to assess indicators of inflammation specific to Th2 responses and proteins related to the protective barrier of the airway’s inner lining. These assessments were conducted using exhaled breath condensate (EBC), which provides insights into peripheral airway conditions of children suffering from food allergies. The study had 24 patients with food allergy and 24 control individuals younger than three years of age with no history of food reaction. The diagnosis of food allergy was based on food allergen-specific IgE and skin prick test positivity in our clinic and oral food testing in selected cases. EBC samples were obtained by Ecoscreen (Jaegar, Hoechberg, Germany). IL4, IL5, IL13 and E-cadherin levels were measured in these samples by enzyme linked immunoassay. The group of children with food allergies, consisting mainly of 14 girls, had a median age of 16 months, whereas the control group, which included 11 girls, had a median age of 15 months (p = 0.89). Comparing the two groups, children with food allergies exhibited notably lower levels of IL-13 in the EBC compared to the control group (median values of 59.14 and 76.36, respectively, p = 0.02). Conversely, the concentration of IL-4 in the EBC was significantly higher in children with food allergies (median values of 1.94 and 1.29, respectively, p = 0.003). However, the levels of IL-5 and e-cadherin showed no significant differences between the two groups (with p-values of 0.74 and 0.09, respectively) as shown in table 1. High level of IL-4 despite the low level of IL-13 in the EBC of children having food allergy may be indicative of an early inflammatory phase that is not yet in the effector phase. Studies about the evolution of this process later in life are needed to assess the role of airway inflammation in children with food allergy who develop asthma. © 2023 IOP Publishing Ltd.
  • No Thumbnail Available
    Item
    Comparing mesh and compressor nebulizers in pulmonary function test in pediatric asthma attacks: A double-blind randomized comparative clinical trial
    (W.B. Saunders Ltd, 2025) Okay B.; Hatipoglu H.U.; Okay Z.U.; Sahin K.; Yasar A.
    Objective: Asthma is a prevalent global health issue, especially affecting children in numerous countries. Our study aimed to determine the most effective nebulizer type by comparing the effects of mesh nebulizers (MNs) and compressor nebulizers (CNs) on spirometry tests in pediatric asthma attacks. Methods: The prospective, double-blind, randomized comparative study was conducted with patients aged 7–15 presenting with asthma attacks. The participating patients were divided into two groups by randomization: those using CNs and those using MNs. A pulmonary function test was performed before and after giving the patients three doses of salbutamol inhaler at 20-minute intervals, and changes in the test were recorded. Results: The increase in peripheral oxygen saturation was higher in the MN group, although this difference was not statistically significant (p = 0.391). However, statistically significant differences were observed in the decrease in respiratory rate (RR;/min; p = 0.002) and the increase in heart rate (/min; p = 0.022). The respiratory function test indicated a higher change in forced vital capacity (FVC) and peak expiratory flow in the MN group than the CN group, although this difference was not statistically significant (p = 0.258 and 0.256). However, statistically significant changes were observed in the forced expiratory volume in 1 second (FEV1) and forced expiratory flow at 25%–75% of FVC (FEF25–75; p = 0.001 and 0.043). Conclusion: MNs show superior improvement in vital signs and pulmonary function, particularly in RR, FEV1, and FEF25–75. MNs may be preferred for more effective treatment despite heart rate elevation. © 2025 Elsevier Ltd